• 대한약학회:학술대회논문집
• /
• 대한약학회 2004년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.143-143
• /
• 2004

• Asian Journal of Business Environment
• /
• 제11권4호
• /
• pp.39-45
• /
• 2021

Purpose: This study is designed to investigate the extent and nature of climate change disclosure of listed pharmaceutical companies of Bangladesh. Research design, data and methodology: In order to perform this research, a content analysis methodology is used. A climate change disclosure index is constructed to examine 12 different climate change disclosure issues. Information is collected from the annual reports of 29 pharmaceutical companies listed on the Dhaka Stock Exchange for the year 2019. Results: This study finds that only 48.28% of the sample companies provided disclosure on at least one issue regarding climate change. 'Energy savings' is the mostly disclosed issue whereas 'Pollution control expenditure', 'Biodiversity conservation initiatives' are the least disclosed issues. Research implication: This study concludes 64.29% of the companies examined, use less than five sentences for climate change disclosure, which depicts unsatisfactory disclosure practices regarding climate change issues. Study findings would be helpful for different industries of Bangladesh to implement efficient climate change reporting Practice. Future studies can be conducted on other industries to obtain more comprehensive result.

• 약학회지
• /
• 제21권3호
• /
• pp.118-134
• /
• 1977

In Korea, antibiotic fermentation industries have just started budding out now. Tetracycline derivative (Pfizer, CKD), Kanamycin (Dongmyung) are produced by fermentation processes. Penicillin, erythromycin, gentamicin, rifamycin, and a few others are being planned for production within a few years by major pharmaceutical and chemical firms in Korea. Reviewing past and present activities in the antibiotic fermentation industries in Korea suggests that the prospects for antibiotics will be very bright.

• 한국미생물·생명공학회지
• /
• 제51권3호
• /
• pp.268-279
• /
• 2023

The pharmaceutical industry in Bangladesh produces a diverse range of antibiotics for human and animal use, however, waste disposal management is inadequate. This results in substantial quantities of antibiotics being discharged into water bodies, which provide suitable environment for the growth of antibiotic-resistant bacteria, capable of spreading resistance genes. This study intended for exploring the bacterial antibiotic resistance profile in adjoining aquatic environmental sources of pharmaceutical manufacturing facilities in Bangladesh. Seven surface water samples were collected from the vicinity of two pharmaceutical industries located in the Savar area and 51 Escherichia coli isolates were identified using both phenotypic and genotypic methods. Antibiotic susceptibility tests revealed the highest percentage of resistance against ampicillin, azithromycin, and nalidixic acid (100%) and the lowest resistance against meropenem (1.96%) out of sixteen different antibiotics tested. 100% of the study E. coli isolates were observed with Multidrug resistance phenotypes, with the Multiple Antibiotic Resistance (MAR) value ranging from 0.6-1.0. Furthermore, 69% of the isolates were Extended Spectrum Beta-Lactamases (ESBL) positive as per the Double Disk Diffusion Synergy Test (DDST). ESBL resistance genes bla_TEM, bla_CTX-M-13, bla_CTX-M-15, and bla_SHV were detected in 70.6% (n = 36), 60.8% (n = 32), 54.9% (n = 28), and 1.96% (n = 1) of the isolates, respectively, by Polymerase Chain Reaction (PCR). Additionally, 15.68% (n = 8) of the isolates were positive for E. coli specific virulence genes in PCR. These findings suggest that pharmaceutical wastewater, if not properly treated, could be a formidable source of antibiotic resistance spread in the surrounding aquatic environment. Therefore, continued surveillance for drug resistance among bacterial populations around drug manufacturing facilities in Bangladesh is necessary, along with proper waste disposal management.

• 품질경영학회지
• /
• 제40권3호
• /
• pp.372-380
• /
• 2012

Purpose: The purpose of this research is to develop the methods for evaluating the business value of a company's technical portfolios. In this study, technical portfolios of 10 major manufacturers and e-Biz industries are examined first from a business model perspective. Subsequently, we suggest future direction of R&D for the pharmaceutical industry by deducing the leading industries sharing similar traits with the pharmaceutical industry. Methods: In order to evaluate and analyze the patents of the major leading industries based on the constituents of a business model, the target patents were selected through the following procedure. Results: First, In this study, using the data obtained from the patent analysis, the differences in the technology portfolios of specific business entities based on the constituents of their business models. Second, deduced business rules of particular business entities through classification analysis and role-model of pharmaceutical industry Conclusion: If enterprise discovers technological change and characters of other enterprise or technology, enterprise could judge a direction of technology which will be developed in the near term and a plan which utilized existing technology to increase enterprise's profits.

• 산업경영시스템학회지
• /
• 제17권31호
• /
• pp.125-139
• /
• 1994

The purpose of this paper is to study the problems to be solved in the marketing strategy aspect by domestic pharmaceutical industry under the competitive market circumstances with multinational pharmaceutic enterprises. The major concern has been paid to the key ideas and practical methods to be needed in strengthening the competitive marketing power of domestic pharmaceutical industry against multinational pharmaceutical enterprises. In this article, the researcher is to analyze the current situations and problems of domestic pharmaceutical industry and finally the researcher is to provide the major ideas concerning the problems to be solved in the marketing strategy aspect by domestic pharmaceutical industries.

• 한국응용과학기술학회지
• /
• 제25권4호
• /
• pp.539-555
• /
• 2008

It is well understood that developing new drugs is one of the highest value-added businesses in a country; however, the current governments' spending in pharmaceutical research and development(R&D) is minimal in Korea. This paper suggests that different governmental bodies should take in charge of different stages of the R&D process in order to maximize the use of limited government research funding. First, during the initial phase of the drug development, including clinical trials, the Ministry of Education, Science and Technology is the most appropriate governmental organization to support the research. For later procedures such as supporting the industries for exporting developed drugs, legislative approvals, and building infrastructure for future clinical trials should be supported by the Ministry of Knowledge and Economy and the Ministry of Health and Welfare along with the Korea Food and Drug Administration(KFDA). The KFDA, which is the main governmental agency approving newly developed drugs in the market, will need to take a crucial responsibility in the initial phase of the pharmaceutical R&D by guiding the industries with timely and proper information. As a first step, it is recommended to set up and operate a center for supporting new drugs, so that the industries can facilitate the development of marketable drugs which meet customers' needs. Later, in order to expedite the process of exporting and getting approvals of the newly developed drugs from foreign countries, it is necessary to develop new approval system, which includes introduction of the Good Manufacturing Practice (GMP), mandatory validation system, and education program for supporting expertise. Lastly, the KFDA needs to take an active role in developing Korean pharmaceutical industries by communicating with other foreign governments with regards to the globalization of the Korean pharmaceutical industries. For example, as a follow up after the Free Trade Agreement(FTA), active discussion on GLP of Mutual Recognition Agreement(MRA) with the United States of America, should be seriously considered.

• Journal of Pharmaceutical Investigation
• /
• 제23권4호
• /
• pp.231-254
• /
• 1993

These days, it is not uncommon that a same kind of drug is circulated globally. However, the qualities of excipients used in the same drug have to be sometimes different depending on the different requirements in the qualities stipulated by each country. For a supplier of pharmaceutical excipients, it is generally necessary to carry out different tests on the same kind of testing criteria depending on the country of destination. Thus, the discrepancies between compendium requirements of pharmaceutical excipients create severe problems in various area of industrial activities. The decision of the United States Pharmacopoeia, European Pharmacopoeia and Japanese Pharmacopoeia Commissions to harmonize the requirements is a unique chance for the industries to overcome these problems. On the other hand, discrepancies of general test methods and requirements in each monograph of pharmaceutical excipient between the compendia valid at present are in most cases extensive. Consequently their harmonization needs a lot of detailed work requiring strong support from the industry. Based on these circumstances, pharmaceutical excipients councils have been established first in U.S.A. and successively in Europe and in Japan to contribute to the harmorization process. We should like to review here the progress since the Orlando Conference in 1991 and comment about the matters at issue with regard to the international harmonization of pharmaceutical excipients.

• 산업경영시스템학회지
• /
• 제44권3호
• /
• pp.192-206
• /
• 2021

The pharmaceutical industry is an industry that provides medicines related to the health and life of the people. The pharmaceutical industry is a traditional regulation industry with the characteristics of R&D(Research and Development), purchasing, manufacturing, distribution and consumption under strict government management. Until now, pharmaceutical companies have continued to make efforts to maintain competitiveness through patent management, new product development, and marketing. However, industries are rapidly changing, including rising costs for developing new products and expanding generic markets. As these changes and uncertainties in the management environment increase, efforts are required to improve the competitiveness of the pharmaceutical industry from a new perspective. In this study, we intend to examine the impact of SCM(Supply Chain Management) dynamic capability of pharmaceutical companies on corporate performance through partnerships to respond to market changes and uncertainties. It was determined that the agility, visibility and flexibility that constitutes the SCM dynamic capabilities would affect the performance of pharmaceutical companies. In this study, the importance of SCM dynamic capabilities and cooperative relationships was identified through surveys by SCM managers of pharmaceutical companies. Consequently, in the pharmaceutical industry, which is a regulatory industry, we have identified that SCM dynamic capabilities and cooperative relationships with partner companies have a significant impact on corporate performance.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.398.3-399
• /
• 2002

Quality control by analytical ability with a certain level of precision and accuracy is important. This is true especially in pharmaceutical industries. for a failure in quality control can result in a failure in drug medication. in turn. sometimes a heavy damage to patient's health condition andlor the worst damage to company's reputation. On this backgroun, Kyungki KFDA prepared test pharmaceutical products, which were distributed to 114 pharmaceutical companies in kyungin Province in year 2000. (omitted)